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Cystic Fibrosis Priority Setting Partnership 
 
PROTOCOL [updated 13 July  2016] 
 
 
1. Purpose of the PSP and background 
The purpose of this protocol is to set out the aims, objectives and commitments of the Cystic Fibrosis Priority 
Setting Partnership (PSP) and the basic roles and responsibilities of the partners therein.  It is recommended 
that the Protocol is reviewed by the Steering Group and updated on at least a quarterly basis. 
 
The James Lind Alliance (JLA) is a non-profit making initiative, established in 2004.  It brings patients, carers 
and clinicians together in Priority Setting Partnerships (PSPs).  These partnerships identify and prioritise 
uncertainties, or ‘unanswered questions’, about the effects of treatments that they agree are the most 
important.  The aim of this is to help ensure that those who fund health research are aware of what really 
matters to both patients and clinicians.  The JLA is coordinated and overseen by the National Institute for 
Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre (NETSCC), based in 
Southampton. 
 
The JLA PSP in Cystic Fibrosis (CF) came about through discussions between the chief investigator (Prof Alan 
Smyth), a person with CF (Oli Rayner) and the CF Trust. Oli Rayner has, until recently, been Cystic Fibrosis 
Trust Special Adviser on Research & Patient Involvement. The CF Trust has funded the PSP, through its 
Venture and Innovation Awards, with matched funding from the University of Nottingham and the Nottingham 
University Hospitals (NUH) Charity. Dr Keith Brownlee (Director of Impact at the CF Trust) has taken part in 
early discussions about the PSP and is a member of the steering committee. Dr Matt Hurley, established the 
CF Unite website (http://cfunite.org) - a collaborative platform which has hosted web based interactive 
seminars, where researchers and patients with CF can discuss research in the field of CF. The JLA PSP in CF 
is distinct from previous PSPs in that patient participants cannot meet together in person because of the risk of 
cross infection. Hence, CF Unite platform, developed by Dr Hurley, will allow online communication within the 
CF community as the PSP progresses. 
 
2. Aims and objectives of the Cystic Fibrosis PSP 
The aim of the CF PSP is to identify the unanswered questions about CF treatment from patient and clinical 
perspectives and then prioritise those that patients and clinicians agree are the most important.  
 
The objectives of the CF PSP are to: 
 
 work with patients and clinicians to identify uncertainties about the effects of CF treatments and 
management of the condition.    
 to agree by consensus a prioritised list of those uncertainties, for research 
 to publicise the results of the PSP and process 
 to take the results to research commissioning bodies to be considered for funding. 
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3. The Steering Group 
 
The CF PSP will be led and managed by the following: 
Patient representative/s:  
 Oli Rayner (Independent Patient Representative) 
 Katie Gathercole (Independent Patient Representative) 
 Zoe Elliott (Parent of child with CF) 
 Jess Nickless (Parent of child with CF) 
 Kirsty Widdowson (Young persons advisory group leader) 
 Keith Brownlee (CF Trust) 
 
Clinical representative/s:  
 Alan Smyth (Respiratory Paediatrician) 
 Tracey Daniels (CF Physiotherapist) 
 Edward Nash (Adult Chest Physician) 
 Sarah Collins (CF Dietician) 
 Beverley Govin (CF Nurse) 
 Alastair Duff (CF Clinical Psychologist) 
 Keith Thompson (CF Pharmacist) 
 Matthew Hurley (Specialist Trainee in Paediatric Respiratory Medicine) 
 Ursula Peaple (CF Commissioner) 
 
The Partnership and the priority setting process will be supported and guided by: 
 University of Nottingham 
o Margaret McPhee (PSP Coordinator) 
o Nicola Rowbotham (Academic Clinical Fellow) 
o Sherie Smith (Cochrane Systematic Reviewer) 
o Paul Leighton (Qualitative Researcher) 
 The James Lind Alliance (JLA) 
o Richard Morley 
The Steering Group includes representation of patient/carer groups and clinicians.  
 
The Steering Group will agree the resources, including time and expertise that they will be able to contribute to 
each stage of the process. The JLA will advise on this.  
 
 
4. The wider Partners 
 
Organisations and individuals will be invited to be involved with the PSP as partners.  Partners are groups or 
individuals who will commit to supporting the PSP by disseminating the PSP survey and helping the PSP to 
gather questions and uncertainties of practical clinical importance relating to the treatment and management of 
the health problem in question.  Partners represent the following groups: 
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 people who have CF 
 family and friends of people who have CF 
 medical doctors, nurses and professionals allied to medicine with clinical experience of treating CF. 
 
It is important that all organisations which can reach and advocate for these groups should be invited to 
become involved in the PSP. The JLA Adviser will take responsibility for ensuring the various stakeholder 
groups are able to contribute equally to the process.  
 
Exclusion criteria 
Some organisations may be judged by the JLA or the Steering Group to have conflicts of interest. These may 
be perceived to adversely affect those organisations’ views, causing unacceptable bias. As this is likely to 
affect the ultimate findings of the PSP, those organisations will not be invited to participate. It is possible, 
however, that interested parties may participate in a purely observational capacity when the Steering Group 
considers it may be helpful. 
 
 
5. The methods the PSP will use 
 
This section describes a schedule of proposed stages through which the PSP aims to fulfil its objectives. The 
process is iterative and dependent on the active participation and contribution of different groups. The methods 
adopted in any stage will be agreed through consultation between the Steering Group members, guided by the 
PSP’s aims and objectives. More details can be found at www.JLAguidebook.org and examples of the work of 
other JLA PSPs can be seen in the ‘The PSPs’ section of the JLA website at www.jla.nihr.ac.uk  
 
Step 1: Identification and invitation of potential partners 
Potential partner organisations will be identified through a process of peer knowledge and consultation, 
through the Steering Group members’ networks. Potential partners will be contacted and informed of the 
establishment and aims of the CF PSP and may be invited to attend and participate in an initial stakeholder 
meeting if this is being arranged.  
 
 
Step 2: Initial stakeholder meeting / awareness raising  
The initial stakeholder meeting / awareness raising will have several key objectives: 
 
 to welcome and introduce potential members of the CF PSP 
 to present the proposed plan for the PSP 
 to initiate discussion, answer questions and address concerns 
 to identify those potential partner organisations which will commit to the PSP and identify individuals who 
will be those organisations’ representatives and the PSP’s principal contacts 
 to establish principles upon which an open, inclusive and transparent mechanism can be based for 
contributing to, reporting and recording the work and progress of the PSP. 
 
Step 3: Identifying treatment uncertainties 
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Each partner will identify a method for soliciting from its members questions and uncertainties of practical 
clinical importance relating to the treatment and management of CF. A period of 12 months will be given to 
complete this exercise.  
 
The methods may be designed according to the nature and membership of each organisation, but must be as 
transparent, inclusive and representative as practicable. Methods may include membership meetings, email 
consultation, postal or web-based questionnaires, internet message boards and focus group work.  
 
Existing sources of information about treatment uncertainties for patients and clinicians will be searched. 
These can include question-answering services for patients and carers and for clinicians; research 
recommendations in systematic reviews and clinical guidelines; protocols for systematic reviews being 
prepared and registers of ongoing research.  
 
The starting point for identifying sources of uncertainties and research recommendations is NHS Evidence: 




Step 4: Refining questions and uncertainties 
The Steering Group will need to have agreed exactly who will be responsible for this stage – the JLA can 
advise on the amount of time likely to be required for its execution. The JLA will participate in this process as 
an observer, to ensure accountability and transparency.  
 
The consultation process will produce “raw” unanswered questions about management, delivery of care,  
diagnosis where it relates to treatment intervention and the effects of treatments. These raw questions will be 
assembled and categorised and refined by Margaret McPhee, Sherie Smith and Nicola Rowbotham into 
“collated indicative questions” which are clear, addressable by research and understandable to all. Similar or 
duplicate questions will be combined where appropriate.  
 
Systematic reviews and guidelines will be identified and checked by Nicola Rowbotham and Sherie Smith to 
see to what extent these refined questions have, or have not, been answered by previous research. 
Sometimes, uncertainties are expressed that can in fact be resolved with reference to existing research 
evidence - ie they are "unrecognised knowns" and not uncertainties. If a question about treatment effects can 
be answered with existing information but this is not known, it suggests that information is not being 
communicated effectively to those who need it. Accordingly, the JLA recommends strongly that PSPs keep a 
record of these 'answerable questions' and deal with them separately from the 'true uncertainties' considered 
during the research priority setting process.  These “answerable questions” will be collated by the PSP team 
and communicated to the Cochrane CF & Genetic Disorders Group and the CF Trust at the end of the process 
– for onward dissemination to the CF community. They may also be the subject of a separate publication. 
 
Uncertainties which are not adequately addressed by previous research will be collated and prepared for entry 
onto the James Lind Alliance website by Sherie Smith and Margaret McPhee This will ensure that the 
uncertainties have been actually checked to be uncertainties. This is the responsibility of the Steering Group, 
which will need to have agreed personnel and resources to carry this accountability. The data should be 
entered onto the JLA website on completion of the priority setting exercise, in order to ensure any updates or 





Step 5: Prioritisation – interim and final stages  
The aim of the final stage of the priority setting process is to prioritise through consensus the identified 
uncertainties relating to the treatment or management of CF. This will be carried out by members of the 
Steering Group and the wider partnership that represents patients and clinicians.  
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 The interim stage, to proceed from a long list of uncertainties to a shorter list to be discussed at the final 
priority setting workshop (e.g. up to 30), may be carried out over email or online, whereby organisations 
consult their membership and choose and rank their top 10 most important uncertainties.  There are 
examples of how other PSPs have achieved this at www.jla.nihr.ac.uk in the Key Documents of the 
Anaesthesia and Perioperative Care PSP section and the Childhood Disability PSP section.   
 
 The final stage, to reach, for example, 10 prioritised uncertainties, is likely to be conducted in an online 
meeting, using group discussions and plenary sessions.  
 
 The methods used for this prioritisation process will be determined by consultation with the partner 
organisations and with the advice of the JLA Adviser. Methods which have been identified as potentially 
useful in this process include: adapted Delphi techniques; expert panels or nominal group techniques; 
consensus development conference; electronic nominal group and online voting; interactive research 
agenda setting and focus groups.  
 
The JLA will facilitate this process and ensure transparency, accountability and fairness. Participants will be 
expected to declare their interests in advance of this meeting. 
 
 
6. Dissemination of findings and research 
 
 
Findings and research  
It is anticipated that the findings of the CF PSP will be reported to funding and research agenda setting 
organisations such as the NIHR and the major research funding charities. Steering Group members and 
partners are expected to develop the prioritised uncertainties into research questions, and to work to establish 
the research needs of those unanswered questions to use when approaching potential funders, or when 
allocating funding for research themselves, if applicable. 
 
Publicity 
As well as alerting funders, partners and Steering Group members are encouraged to publish the findings of 
the CF PSP using both internal and external communication mechanisms. The Steering Group may capture 
and publicise the results through descriptive reports of the process itself in Plain English. This exercise will be 
distinct from the production of an academic paper, which the partners are also encouraged to do. However, 
production of an academic paper should not take precedence over publicising of the final results.  
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7. Agreement of the Steering Group 
 
 
Signed by the Steering Group  
 
The undersigned agree to follow the CF Priority Setting Protocol.   
 
 













Richard Morley, The James Lind Alliance  
 
……………………………………………………………………………………………… 
 
Date: ……………………………………….. 
 
